Sun Pharma Advanced Research Company Limited investor presentation summary

Investor presentation of 8 Jan 2026, summarised by AI from the filing.

Annual fixed cost savings of about $10 million achieved through headcount reduction and lab center consolidation.

Key takeaways

1. Change Annual fixed cost savings of about $10 million achieved through headcount reduction and lab center consolidation.
2. Risk Early-stage portfolio with key assets yet to have early clinical proof of concept; significant additional resources needed.

Original filing on BSE

Sun Pharma Advanced Research Company Limited Q1 FY27 results

As filed: Revenue ₹39.9 cr (+299% year on year), EBITDA −₹34.0 cr, PAT −₹20.8 cr, EBITDA margin -85.2%.

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹1,853 cr (+300% year on year), EBITDA ₹1,773 cr, PAT ₹1,761 cr, EBITDA margin 95.7%. Score 100 of 100, Above trend. Revenue growth was well above the company's own trend. Tax rate 0%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +47.7% in 30 days (Nifty 500: +2.9%).
• Q3 FY26: Revenue ₹8.5 cr, EBITDA −₹56.6 cr, PAT −₹80.4 cr, EBITDA margin -670.3%. Not scored. Too small to score: quarter revenue ₹8.5 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: −9.8% in 30 days (Nifty 500: −5.9%).
• Q2 FY26: Revenue ₹8.0 cr, EBITDA −₹65.0 cr, PAT −₹76.0 cr, EBITDA margin -812.5%. Not scored. Too small to score: quarter revenue ₹8.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: +4.8% in 30 days (Nifty 500: −0.8%).
• Q1 FY26: Revenue ₹10.0 cr, EBITDA −₹52.0 cr, PAT −₹52.0 cr, EBITDA margin -520.0%. Not scored. Too small to score: quarter revenue ₹10.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: −2.0% in 30 days (Nifty 500: +0.8%).
• Q4 FY25: Revenue ₹27.0 cr (+59% year on year), EBITDA −₹53.0 cr, PAT −₹60.0 cr, EBITDA margin -196.3%. Score 45 of 100, In line with trend. Not enough history for a trend yet: scored on growth alone. Share price after the results: −5.8% in 30 days (Nifty 500: +0.3%).
• Q3 FY25: Revenue ₹15.0 cr, EBITDA −₹73.0 cr, PAT −₹80.0 cr, EBITDA margin -486.7%. Not scored. Too small to score: quarter revenue ₹15.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.
• Q2 FY25: Revenue ₹13.0 cr, EBITDA −₹103 cr, PAT −₹107 cr, EBITDA margin -792.3%. Not scored. Too small to score: quarter revenue ₹13.0 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little.

Past price moves after results do not indicate future moves. Not a recommendation.

Sun Pharma Advanced Research Company Limited earnings call, investor presentation and press release summaries

• Other events: Investor presentation (8 Jan 2026), Investor presentation (31 Dec 2025)